Business Description
Cumberland Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2307701092
Total Employee Number:
93Description
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.09 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | -8.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.9 | |||||
Beneish M-Score | -2.82 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.3 | |||||
3-Year EBITDA Growth Rate | 105.6 | |||||
3-Year EPS without NRI Growth Rate | -5 | |||||
3-Year FCF Growth Rate | -9.9 | |||||
3-Year Book Growth Rate | -13 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.41 | |||||
9-Day RSI | 78.26 | |||||
14-Day RSI | 73.4 | |||||
3-1 Month Momentum % | 101.63 | |||||
6-1 Month Momentum % | 52.09 | |||||
12-1 Month Momentum % | 138.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.95 | |||||
Quick Ratio | 0.79 | |||||
Cash Ratio | 0.32 | |||||
Days Inventory | 223.19 | |||||
Days Sales Outstanding | 108.69 | |||||
Days Payable | 776.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 8.15 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.89 | |||||
Operating Margin % | -17.2 | |||||
Net Margin % | -17.61 | |||||
EBITDA Margin % | -2.99 | |||||
FCF Margin % | 5.84 | |||||
OCF Margin % | 3.39 | |||||
ROE % | -28.56 | |||||
ROA % | -10.5 | |||||
ROIC % | -14.16 | |||||
3-Year ROIIC % | -51.62 | |||||
ROC (Joel Greenblatt) % | -86.47 | |||||
ROCE % | -16.42 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 162.01 | |||||
PS Ratio | 2.3 | |||||
PB Ratio | 4.5 | |||||
Price-to-Tangible-Book | 12.23 | |||||
Price-to-Free-Cash-Flow | 39.79 | |||||
Price-to-Operating-Cash-Flow | 68.21 | |||||
EV-to-EBIT | -14.12 | |||||
EV-to-EBITDA | -76.41 | |||||
EV-to-Revenue | 2.28 | |||||
EV-to-FCF | 39.14 | |||||
Price-to-GF-Value | 3 | |||||
Price-to-Projected-FCF | 1.72 | |||||
Price-to-Median-PS-Value | 1.58 | |||||
Earnings Yield (Greenblatt) % | -7.08 | |||||
FCF Yield % | 2.52 | |||||
Forward Rate of Return (Yacktman) % | -0.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CPIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Cumberland Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 41.939 | ||
| EPS (TTM) ($) | -0.49 | ||
| Beta | -0.8373 | ||
| 3-Year Sharpe Ratio | 0.78 | ||
| 3-Year Sortino Ratio | 2.13 | ||
| Volatility % | 116.14 | ||
| 14-Day RSI | 73.4 | ||
| 14-Day ATR ($) | 0.368835 | ||
| 20-Day SMA ($) | 5.834 | ||
| 12-1 Month Momentum % | 138.08 | ||
| 52-Week Range ($) | 1.85 - 6.9316 | ||
| Shares Outstanding (Mil) | 14.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cumberland Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cumberland Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 36 days | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 4.53 (+6.84%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 4.53 (+6.84%) | ||
| General meeting for 2026 | 2026-04-21 09:30 | 3.15 (-0.94%) | ||
| Annual report for 2025 | 2026-03-09 | 3.50 (+0.29%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-03 16:30 | 4.84 (-0.62%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 4.84 (-0.62%) |
Show
Entries
Cumberland Pharmaceuticals Inc Frequently Asked Questions
What is Cumberland Pharmaceuticals Inc(CPIX)'s stock price today?
The current price of CPIX is $6.48. The 52 week high of CPIX is $6.93 and 52 week low is $1.85.
When is next earnings date of Cumberland Pharmaceuticals Inc(CPIX)?
The next earnings date of Cumberland Pharmaceuticals Inc(CPIX) is 2026-08-05 Est..
Does Cumberland Pharmaceuticals Inc(CPIX) pay dividends? If so, how much?
Cumberland Pharmaceuticals Inc(CPIX) does not pay dividend.
Guru Commentaries on NAS:CPIX
No articles.
Press Release
Articles on Cumberland Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers